How do MedTech manufacturers use design controls to build product conformity in from the start, rather than demonstrating it at the end of development?
We set up the design controls process per ISO 13485:2016 Section 7.3 and FDA 21 CFR Part 820.30 as end-to-end governance: from user needs and design inputs through verification and validation to design transfer into production. The essential factor is rarely a single document, it is the missing traceability. Anyone who reconstructs traceability from requirement to evidence only shortly before submission is building the Design History File backwards instead of maintaining it.
- MedTech
- IVD
Overview
Which design controls challenges arise in MedTech development?
Support from user needs to design transfer · ISO 13485:2016 Section 7.3, FDA 21 CFR Part 820.30, IEC 62366-1, ISO 14971
Last updated: 2026-06-13
Design controls per ISO 13485:2016 Section 7.3 and FDA 21 CFR Part 820.30 are not a documentary reconstruction at the end of development, they are a process governance tool. In practice they are often the structural weak point where development projects stall before submission. Four recurring gaps:
- Requirements are not captured completely or are not traceable to verification. Without end-to-end traceability from user needs through design inputs to evidence, it is not possible under ISO 13485:2016 Section 7.3 to demonstrate that every requirement has been verified.
- The Design History File is incomplete, inconsistent, or not maintained in an audit-proof manner. Under FDA 21 CFR Part 820 it must be complete at the time of an inspection: development decisions, design changes, reviews, and verification and validation records.
- Design reviews are held pro forma, without any real function in defect prevention. A review at a defined milestone is a decision gate under ISO 13485:2016 Section 7.3, not a meeting documented after the fact.
- Design transfer into production takes place without complete qualification documentation. Manufacturing specifications, process qualification, and release must evidence the transition from development into series production, otherwise a gap opens up between the verified design and the manufactured product.
Services
How we support you
User Needs & Design Inputs
Structured capture of user needs per IEC 62366-1 and their translation into complete, verifiable design inputs. Building the traceability matrix from the outset, linking every requirement to its later evidence.
Learn more →Design Reviews
Structured design reviews at defined milestones as decision gates rather than pro forma meetings. Review records with documented actions and a release decision per ISO 13485:2016 Section 7.3.
Verification & Validation
V&V plans per ISO 13485:2016 Section 7.3 and FDA 21 CFR Part 820.30: verification against the design inputs, validation against the user needs, with each protocol linked to the traceability matrix.
Learn more →Design History File
Building and audit-proof maintenance of the Design History File per FDA 21 CFR Part 820, covering all design decisions, changes, reviews, and verification and validation results, kept inspection-ready as a single coherent archive.
Design Transfer
Handover of development outputs to production: manufacturing specifications, process qualification, first article inspection, and release documentation that evidence the transition from the verified design to series production.
Learn more →Risk Management Integration
Integration of design controls with risk management per ISO 14971, so that identified risks feed back into design inputs and verification evidence instead of being managed in parallel.
Learn more →How we work together
What it comes down to
Design controls per ISO 13485:2016 Section 7.3 and FDA 21 CFR Part 820.30 are not a documentation obligation to be worked through at the end, they are a governance process with a fixed sequence. User needs are translated into verifiable design inputs. The inputs give rise to design outputs. Verification demonstrates that the outputs meet the inputs. Validation demonstrates on the final product that the user needs are met. Each of these links is connected through the traceability matrix. Anyone who skips a stage or documents it only late loses traceability, and with it the evidence that ISO 13485:2016 Section 7.3 requires for every single requirement.
The sore point therefore rarely lies in a single document, it lies in timing. If traceability is carried along from the outset and the Design History File is built up continuously rather than backwards under FDA 21 CFR Part 820, then reviews are genuine decision gates and design transfer into production is the continuation of a verified design rather than a retrofitted bridge. This is exactly where we come in: the structure is created early, so that corrections occur during development, where they are cheap, and not during the inspection, where they become expensive.
Our approach
Our approach
Step
Result
Define design inputs
Complete, verifiable design inputs derived from the user needs; traceability matrix established.
Design outputs & reviews
Design outputs checked against the inputs; review records with a release decision at the milestones.
Verification
Evidence that the design outputs meet the design inputs; verification protocols linked in the traceability matrix.
Validation
Evidence on the final product that the user needs are met; validation results documented.
Design History File
Complete, audit-proof development archive per FDA 21 CFR Part 820, inspection-ready.
Design transfer
Development outputs handed over to production; manufacturing specifications and release documentation in place.
Common pitfalls
Where projects commonly fail
The traceability matrix is built only shortly before submission.
If traceability from requirement to evidence is reconstructed after the fact, individual links are missing, and under ISO 13485:2016 Section 7.3 it is not possible to demonstrate verification for every requirement.
Verification and validation are confused or merged.
Verification checks the design against the design inputs, validation checks the final product against the user needs. Anyone who performs only one of them leaves open one of the levels of evidence required under ISO 13485:2016 Section 7.3 and FDA 21 CFR Part 820.30.
The Design History File is treated as a collection folder rather than a maintained archive.
Under FDA 21 CFR Part 820 it must be complete and audit-proof at the time of an inspection; loosely filed records without version status generate findings.
Design reviews are documented pro forma.
A review under ISO 13485:2016 Section 7.3 is a decision gate with documented actions; a record created after the fact without a traceable decision does not fulfill its defect-prevention function.
Design transfer takes place without complete qualification of the production processes.
If manufacturing specifications or process qualification are missing, a gap opens up between the verified design and the manufactured product, leading to deviations in series production.
FAQ
Frequently asked questions
Sources
- ISO 13485:2016 - Medical devices quality management systems, Section 7.3 (Design and development)
- FDA 21 CFR Part 820 - Quality System Regulation, § 820.30 (Design Controls)
- IEC 62366-1:2015 - Medical devices, Application of usability engineering
- ISO 14971 - Application of risk management to medical devices
- Regulation (EU) 2017/745 (MDR) - primary text
- https://theentourage.de/expertise/design-controls/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Related insights
All insights →Regulations & standards considered
- ISO 13485:2016 Section 7.3 (Design and development of medical devices / design controls)
- FDA 21 CFR Part 820.30 (Design Controls)
- FDA 21 CFR Part 820 (Quality System Regulation, incl. Design History File)
- EU 2017/745 (MDR)
- IEC 62366-1:2015 (Usability engineering)
- ISO 14971 (Application of risk management to medical devices)
Related topics
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences